Xudong Xu, MD
Family Medicine · Houston, TXNPI 1992701908
Payments from drug & device makers
Across 1,231 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- AstraZeneca$6K
- Amgen$3K
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Bayer$1K
- plus $12K from 44 others
What the payments were for
- Consulting fees$2,1006%
- Travel & lodging$5672%
- Food & beverage$29,88192%
- Education$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,632 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 1,041 | $709,000 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 247 | $299,186 |
| FarxigaDapagliflozin Propanediol | 260 | $286,075 |
| TrulicityDulaglutide | 114 | $211,687 |
| TradjentaLinagliptin | 126 | $139,972 |
| LinzessLinaclotide | 112 | $117,219 |
| JardianceEmpagliflozin | 97 | $107,913 |
| OzempicSemaglutide | 78 | $97,820 |
| MounjaroTirzepatide | 69 | $97,004 |
| JanuviaSitagliptin Phosphate | 73 | $96,833 |
| ProliaDenosumab | 49 | $86,198 |
| ZenpepLipase/Protease/Amylase | 35 | $85,746 |
| KerendiaFinerenone | 85 | $82,338 |
| RybelsusSemaglutide | 43 | $81,124 |
| Metformin Er GastricMetformin Hcl | 30 | $80,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Tradjenta, Jardiance | $848 | $547,072470 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,875 | $308,690183 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $5,919 | $296,394276 claims |
| Novo NordiskOzempic, Rybelsus | $1,597 | $178,944121 claims |
| AbbVieLinzess, Creon, Restasis | $1,083 | $170,460161 claims |
| MerckJanuvia | $1,128 | $96,83373 claims |
| AmgenProlia | $3,108 | $86,19849 claims |
| Aimmune Therapeutics, Inc.Zenpep | $386 | $85,74635 claims |
| BayerKerendia | $1,168 | $82,33885 claims |
| PfizerEliquis | $439 | $72,86457 claims |
| GSKTrelegy Ellipta | $1,145 | $39,94563 claims |
| Johnson & JohnsonXarelto | $946 | $38,03940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.